Business Wire

INNIO

22.9.2022 14:32:59 CEST | Business Wire | Press release

Share
On the Path to Net Zero: TIWAG Subsidiary TINEXT to Supply INNIO’s Primary Operations in Jenbach with Green Hydrogen

INNIO and TIWAG today announce that TINEXT, a TIWAG (Tiroler Wasserkraft AG) subsidiary, will supply INNIO’s primary operations in Jenbach with green hydrogen (H2) by 2025. At the same time, excess power and heat will be fed into the local power grid and district heating network. Once sufficient quantities of green hydrogen are available, additional areas of application are planned, such as supplying an INNIO plant gas station or refueling local logistics companies’ vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220922005259/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vice president and site manager of INNIO's Jenbacher site Martin Mühlbacher, TIWAG managing director Dipl.-Ing Thomas Gasser, and INNIO president and CEO Dr. Olaf Berlien. (Photo: Business Wire)

As part of the joint project, INNIO will install an electrolysis unit on the premises of TIWAG’s Achensee power plant that will convert green electricity into green hydrogen. In turn, TINEXT will construct the compression and storage terminals. The hydrogen, a key component in the energy transition, will be transported via pipeline from TINEXT to INNIO’s main operations in Jenbach, where it will primarily be used for hydrogen engine test runs.

“The hydrogen agreement with TIWAG and TINEXT is another milestone on our path to net zero at our site in Jenbach,” said Olaf Berlien, president and CEO of INNIO. “We have committed to reducing emissions from our production sites around the world by up to 50% by 2030. The products of the future are being developed here in our INNIO360 Energy Lab, where we demonstrate how the energy transition works.”

“Using green hydrogen to generate power is an important step on INNIO’s journey to significantly reduce the carbon footprint of the site in Jenbach,” said Martin Mühlbacher, vice president and site manager in Jenbach. “Along with the use of a photovoltaic system, hydropower plant, battery storage, storage water heater (power-to-heat), and electromobility, this will make an important contribution to implementing our broad-ranging sustainability strategy.”

“This pioneering hydrogen project is a central element of Tyrol’s energy strategy of phasing out the use of fossil fuels. With this agreement, INNIO and TIWAG are showing how the transition to an energy-autonomous and climate-neutral energy supply for industrial companies can be realized,” commented TIWAG managing director Dipl.-Ing Thomas Gasser. “TIWAG has been using hydropower to generate green electricity in Jenbach for almost 100 years. As of this summer, this is supported by a large photovoltaic system. It is all the more gratifying that our subsidiary TINEXT is now suppling green hydrogen for our customer and partner INNIO at this location, which has a long tradition in power generation.”

The availability of green hydrogen is an important prerequisite for the sustainable, economic, and timely implementation of INNIO’s hydrogen strategy. The company began offering all new Jenbacher engines with a “Ready for H2” option this year.

About TIWAG

TIWAG, the state energy utility owned by the State of Tyrol, is tasked with providing a secure, sustainable, and integrated energy supply for Tyrol. The TIWAG Group supports the European and national energy goals and is a driving force behind the ecological transition in Tyrol’s power, gas, and heat supply. TINEXT – TIWAG Next Energy Solutions GmbH, the 100% subsidiary established in 2021, supports the energy transition in the fields of hydrogen, photovoltaics, renewable heat, and electromobility.

About INNIO

INNIO is a leading energy solution and service provider that empowers industries and communities to make sustainable energy work today. With our product brands Jenbacher and Waukesha and our digital platform myPlant, INNIO offers innovative solutions for the power generation and compression segments that help industries and communities generate and manage energy sustainably while navigating the fast-changing landscape of traditional and green energy sources. We are individual in scope, but global in scale. With our flexible, scalable, and resilient energy solutions and services, we are enabling our customers to manage the energy transition along the energy value chain wherever they are in their transition journey.

INNIO is headquartered in Jenbach (Austria), with other primary operations in Waukesha (Wisconsin, U.S.) and Welland (Ontario, Canada). A team of more than 3,500 experts provides life-cycle support to the more than 54,000 delivered engines globally through a service network in more than 80 countries.

INNIO’s ESG Risk Rating places it number one of more than 500 worldwide companies in the machinery industry assessed by Sustainalytics.

For more information, visit INNIO’s website at www.innio.com. Follow INNIO on Twitter and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005259/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye